Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1–42 antibodies in Alzheimer's disease patients

详细信息    查看全文

• 作者：Elisa Conti ; Gloria Galimberti ; Lucio Tremolizzo ; Aless ; ro Masetto ; Diletta Cereda ; Clara Zanchi ; Fabrizio Piazza ; Marco Casati ; Valeria Isella ; Ildebr ; o Appollonio ; Carlo Ferrarese
• 关键词：AChEI ; Anti-Abeta 1– ; 42 antibodies ; Alzheimer's disease
• 刊名：Neuroscience Letters
• 出版年：2010
• 出版时间：17 December 2010
• 年：2010
• 卷：486
• 期：3
• 页码：193-196
• 全文大小：173 K

文摘

Acetyl-cholinesterase inhibitors (AChEI) are drugs frequently prescribed for the treatment of Alzheimer's disease (AD), exerting an effect on cognition, as well as on behavioural and psychological symptoms of dementia and activities of daily living. The efficacy of AChEI may be ascribed not only to the activation of cholinergic transmission, but also to other mechanisms, among which a putative regulation of the immune response has already been hypothesized. In the present study, we evaluated, in a cross-sectional sample of 66 AD patients and 48 healthy controls, the putative influence of AChEI on anti-Abeta 1–42 antibody plasma levels by ELISA assay. AD patients receiving AChEI therapy showed increased plasma levels of anti-Abeta 1–42 antibodies respect to untreated AD patients and antibodies levels similar to those of healthy controls, both before and after normalization by total IgG values. Our results support a potential role of AChEI in the modulation of the immune response against Abeta. We suggest that a strategy aimed at increasing the endogenous response against this peptide might represent an interesting therapeutic target to be further investigated.